Hairy cell leukemia (HCL) is a rare chronic B cell leukemia morphologically characterized by cells with an abundant cytoplasm and hair-like projections that can be found in the peripheral blood and bone marrow. The treatment for HCL is splenectomy or chemotherapy with the purine analogs pentostatin and cladribine. However, patients continue to relapse. Retreatment with the same or alternate purine analogs produces lower response rates and a shorter duration of response. Fludarabine is another purine analog widely used in treating indolent lymphoid cancers, often in combination with rituximab. Here, we report a case of HCL variant in a 60-year-old man who experienced multiple relapses after splenectomy and retreatment with cladribine. The patient was then treated with fludarabine and rituximab combination chemotherapy. After the treatment, he achieved complete remission that continued for 35 months.
Approximately 90% of HCL patients have splenomegaly, and splenectomy was the first effective treatment for this disease. 3 Although splenectomy does not produce pathologic remission, peripheral blood counts return to normal in 40% -70% of patients and overall 5-year survival rates are 60% -70%. 4, 5 Patients with HCL benefit from splenectomy compared with non-splenectomized patients, 6 and they respond better and faster to the following therapy. These results suggest that splenectomy should be considered for patients with HCL because it corrects cytopenias and removes a significant bulk of the disease. 7 Currently, the In other study, patients who were positive for minimal residual disease (MRD) after treatment with cladribine showed a high level of expression of CD20 with more than 100,000 sites per cell. 13 Cells with high levels of CD20 expression represent a target for the humanized anti-CD20 monoclonal antibody (mAB) rituximab. 13 FR fludarabine and rituximab, M male, CDA cladribine (2-chlorodeoxyadenosine), PFS progression free survival, R rituximab, CR complete remission, 
